Humacyte, Inc.
Datakwaliteit: 100%
HUMAW
Nasdaq
Manufacturing
Chemicals
€ 0,09
▼
€ 0,02
(-17,74%)
Marktkapitalisatie: 14,30 M
Prijs
€ 0,09
Marktkapitalisatie
14,30 M
Dagbereik
€ 0,09 — € 0,11
52-Weeksbereik
€ 0,09 — € 0,11
Volume
13.868
Openen € 0,23
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -105,93 M
Capital intensive — 43,38% of revenue goes to capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-93,04%
Net Margin-2003,58%
Op. Margin-5306,04%
Veiligheid
Debt / Equity
N/A
Current Ratio1,62
Interest Coverage-9,61
Waardering
PE (TTM)
-0,35
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,4 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,5 |
| Net Margin % | -2003,6 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2,04 M | Net Income (TTM) | -40,83 M |
| ROE | N/A | ROA | -35,46% |
| Gross Margin | N/A | Operating Margin | -5306,04% |
| Net Margin | -2003,58% | Free Cash Flow (TTM) | -105,93 M |
| ROIC | -93,04% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1,62 |
| Interest Coverage | -9,61 | Asset Turnover | 0,02 |
| Working Capital | 15,77 M | Tangible Book Value | -4,75 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,35 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 7,02 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -740,86% | ||
| Market Cap | 14,30 M | Enterprise Value | -5,19 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,26 | Revenue / Share | 0,01 |
| FCF / Share | -0,67 | OCF / Share | -0,66 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 43,38% | FCF Conversion | 259,41% |
| SBC-Adj. FCF | -114,76 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 2,04 M | — | — | — | — |
| Net Income | -40,83 M | -148,70 M | -110,78 M | -11,97 M | -233.333,0 |
| EPS (Diluted) | -0,26 | -1,26 | -1,07 | -0,12 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -108,14 M | -114,40 M | -100,05 M | -84,58 M | -249.524,0 |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 69,30 M | 88,60 M | 76,55 M | 63,26 M | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 11,25 M | 9,28 M | 6,60 M | 6,20 M | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 116,37 M | 137,87 M | 128,22 M | 204,30 M | 101,26 M |
| Total Liabilities | 113,26 M | 190,54 M | 114,68 M | 87,37 M | 2,10 M |
| Shareholders' Equity | 3,11 M | -52,67 M | 13,55 M | 116,93 M | 5,00 M |
| Total Debt | 35,44 M | — | — | — | — |
| Cash & Equivalents | 50,50 M | 44,94 M | 80,45 M | 149,77 M | 1,09 M |
| Current Assets | 67,80 M | 47,86 M | 83,28 M | 154,21 M | 1,24 M |
| Current Liabilities | 18,37 M | 19,95 M | 18,44 M | 19,58 M | 247.945,0 |
{"event":"ticker_viewed","properties":{"ticker":"HUMAW","listing_kind":"stock","pathname":"/stocks/humaw","exchange":"Nasdaq","country":"US"}}